<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743976</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00022107</org_study_id>
    <secondary_id>R01NS057594</secondary_id>
    <nct_id>NCT01743976</nct_id>
  </id_info>
  <brief_title>Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain</brief_title>
  <official_title>Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on laboratory studies, donepezil will improve pain relief more than placebo in patients&#xD;
      with chronic neuropathic pain who are currently taking gabapentin or pregabalin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators are currently examining in the laboratory the mechanisms which lead to&#xD;
      sprouting of noradrenergic fibers in the spinal cord in models of chronic pain as well as the&#xD;
      mechanisms that lead to a novel noradrenergic - cholinergic circuit in the spinal cord. In&#xD;
      addition to examining the circumstances which generate this increased capacity for analgesia&#xD;
      and the mechanisms by which they occur, investigators will test in this protocol whether&#xD;
      approved and experimental treatments for neuropathic pain exploit this increased capacity.&#xD;
&#xD;
      This study is in patients with neuropathic pain taking gabapentin or pregabalin, and will&#xD;
      test the clinical relevance of these preclinical data by comparing placebo to the&#xD;
      cholinesterase inhibitor. Investigators focus not only on mechanistic hypotheses in the&#xD;
      laboratory studies, but also on practical applications, using clinically approved drugs,&#xD;
      including gabapentin and pregabalin to activate noradrenergic activity and donepezil&#xD;
      (Aricept®), approved for the treatment of Alzheimer's dementia, but not previously tested to&#xD;
      treat neuropathic pain, to inhibit cholinesterase. Each of these drugs may act by mechanisms&#xD;
      in addition to those involved in descending noradrenergic inhibition, but investigators&#xD;
      hypothesize that the therapeutic strength of their combination relies heavily on this cascade&#xD;
      engendered by noradrenergic sprouting and altered α2-adrenoceptor function. The proposed&#xD;
      studies will provide critical tests of this hypothesis and critical information to guide more&#xD;
      effective clinical therapy of neuropathic pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit subjects&#xD;
  </why_stopped>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Actual">October 23, 2013</completion_date>
  <primary_completion_date type="Actual">October 23, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>McGill Short Form Pain Questionnaire (SF MPQ) Visual Analog Scale (VAS) Pain Intensity</measure>
    <time_frame>baseline</time_frame>
    <description>A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>McGill Short Form Pain Questionnaire (SF MPQ) Visual Analog Scale (VAS) Pain Intensity</measure>
    <time_frame>Week 8: last week of study drug treatment</time_frame>
    <description>A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>McGill Short Form Pain Questionnaire (SF MPQ) Visual Analog Scale (VAS) Pain Intensity</measure>
    <time_frame>Week 10: last week of washout</time_frame>
    <description>A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average From Baseline Profile of Mood States-Short Form (POMS-SF) at 10 Weeks</measure>
    <time_frame>baseline, week 8 after baseline, and week 10 after baseline</time_frame>
    <description>The questionnaire records total mood disturbance. The scale ranges from 0-100 with a greater number denoting a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Rescue Treatment</measure>
    <time_frame>Days: baseline, week 8 after baseline, and week 10 after baseline</time_frame>
    <description>Questionnaires detailing the amount of rescue pain medications will be completed twice daily.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>donepezil 5 mg every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sugar pill) every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>donepezil 5 mg once daily for 6 weeks</description>
    <arm_group_label>Donepezil</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo or sugar pill will be taken once daily for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of diabetic neuropathy or failed back syndrome with neuropathic symptoms&#xD;
&#xD;
          -  Age 18-80&#xD;
&#xD;
          -  Taking a stable dose of gabapentin or pregabalin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women or women of child-bearing potential not willing to practice a reliable&#xD;
             form of birth control&#xD;
&#xD;
          -  Allergy to donepezil or other piperidine derivatives (including fentanyl, alfentanil,&#xD;
             sulfentanil, remifentanyl, demerol, tramadol, loperamide, diphenoxylate, betaprodine,&#xD;
             alphaprodine, ethopropazine, anileridine, piminodine,&#xD;
             1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP),loratadine, fexofenadine&#xD;
&#xD;
          -  Unstable medical conditions including cardiac, pulmonary, renal or hepatic diseases&#xD;
             that, in the opinion of the investigator, would preclude patients from finishing the&#xD;
             trial&#xD;
&#xD;
          -  Any person with pending litigation&#xD;
&#xD;
          -  A history of major psychosis requiring hospitalization within the last three years&#xD;
&#xD;
          -  Non-English speaking, illiterate, unable to comprehend consent&#xD;
&#xD;
          -  Lack of contact information&#xD;
&#xD;
          -  Uncontrolled narrow-angle glaucoma&#xD;
&#xD;
          -  Currently being treatment with thioridazine (Mellaril)&#xD;
&#xD;
          -  Patients taking opioids will be excluded if they are taking a dosage that exceeds an&#xD;
             equivalent of 30 mg of morphine per day&#xD;
&#xD;
          -  Patients taking more than one regular (not rescue) medication for pain&#xD;
&#xD;
          -  Patients taking donepezil for dementia&#xD;
&#xD;
          -  Patients with a baseline pain score less than 2 (0-10 scale) or greater than 8 (0-10)&#xD;
             will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Eisenach, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <results_first_submitted>September 22, 2020</results_first_submitted>
  <results_first_submitted_qc>November 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2020</results_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropathic pain</keyword>
  <keyword>diabetic neuropathy</keyword>
  <keyword>neuropathic pain after back surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 19, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT01743976/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT01743976/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Donepezil</title>
          <description>donepezil 5 mg every day&#xD;
Donepezil: donepezil 5 mg once daily for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (sugar pill) every day&#xD;
Placebo: placebo or sugar pill will be taken once daily for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Donepezil</title>
          <description>donepezil 5 mg every day&#xD;
Donepezil: donepezil 5 mg once daily for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (sugar pill) every day&#xD;
Placebo: placebo or sugar pill will be taken once daily for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="38" upper_limit="50"/>
                    <measurement group_id="B2" value="52" lower_limit="48" upper_limit="69"/>
                    <measurement group_id="B3" value="50" lower_limit="38" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>McGill Short Form Pain Questionnaire (SF MPQ) Visual Analog Scale (VAS) Pain Intensity</title>
        <description>A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil 5 mg every day&#xD;
Donepezil: donepezil 5 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sugar pill) every day&#xD;
Placebo: placebo or sugar pill will be taken once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>McGill Short Form Pain Questionnaire (SF MPQ) Visual Analog Scale (VAS) Pain Intensity</title>
          <description>A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.</description>
          <units>units on the scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.3" upper_limit="4.7"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.6" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average From Baseline Profile of Mood States-Short Form (POMS-SF) at 10 Weeks</title>
        <description>The questionnaire records total mood disturbance. The scale ranges from 0-100 with a greater number denoting a worse outcome.</description>
        <time_frame>baseline, week 8 after baseline, and week 10 after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil 5 mg every day&#xD;
Donepezil: donepezil 5 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sugar pill) every day&#xD;
Placebo: placebo or sugar pill will be taken once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average From Baseline Profile of Mood States-Short Form (POMS-SF) at 10 Weeks</title>
          <description>The questionnaire records total mood disturbance. The scale ranges from 0-100 with a greater number denoting a worse outcome.</description>
          <units>Total score on POM-S scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="26" upper_limit="28"/>
                    <measurement group_id="O2" value="53" lower_limit="23" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 after Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="23" upper_limit="27"/>
                    <measurement group_id="O2" value="24" lower_limit="16" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 after Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="27" upper_limit="40"/>
                    <measurement group_id="O2" value="24" lower_limit="15" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Rescue Treatment</title>
        <description>Questionnaires detailing the amount of rescue pain medications will be completed twice daily.</description>
        <time_frame>Days: baseline, week 8 after baseline, and week 10 after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil 5 mg every day&#xD;
Donepezil: donepezil 5 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sugar pill) every day&#xD;
Placebo: placebo or sugar pill will be taken once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Rescue Treatment</title>
          <description>Questionnaires detailing the amount of rescue pain medications will be completed twice daily.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 after Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 after Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>McGill Short Form Pain Questionnaire (SF MPQ) Visual Analog Scale (VAS) Pain Intensity</title>
        <description>A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.</description>
        <time_frame>Week 8: last week of study drug treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil 5 mg every day&#xD;
Donepezil: donepezil 5 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sugar pill) every day&#xD;
Placebo: placebo or sugar pill will be taken once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>McGill Short Form Pain Questionnaire (SF MPQ) Visual Analog Scale (VAS) Pain Intensity</title>
          <description>A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.</description>
          <units>units on the scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.1" upper_limit="1.6"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.1" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>McGill Short Form Pain Questionnaire (SF MPQ) Visual Analog Scale (VAS) Pain Intensity</title>
        <description>A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.</description>
        <time_frame>Week 10: last week of washout</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil 5 mg every day&#xD;
Donepezil: donepezil 5 mg once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sugar pill) every day&#xD;
Placebo: placebo or sugar pill will be taken once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>McGill Short Form Pain Questionnaire (SF MPQ) Visual Analog Scale (VAS) Pain Intensity</title>
          <description>A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.</description>
          <units>units on the scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="0.7"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.1" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Donepezil</title>
          <description>donepezil 5 mg every day&#xD;
Donepezil: donepezil 5 mg once daily for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (sugar pill) every day&#xD;
Placebo: placebo or sugar pill will be taken once daily for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James C. Eisenach</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-716-4182</phone>
      <email>jimeisenach@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

